Roche Reports the EMA’s Approval of Vabysmo Prefilled Syringe (PFS) for three Retinal Conditions Causing Blindness
Shots:
- Roche's Vabysmo (faricimab) 6mg prefilled syringe (PFS) has been approved by the EMA for treating nAMD, DME & macular edema from RVO. It is an intravitreal injection, offering the same medication as the 6mg Vabysmo vials in a ready-to-use format
- Vabysmo has shown significant vision & anatomical improvements in patients with nAMD, DME & RVO
- Vabysmo is the first bispecific antibody approved for the eye, targeting and inhibiting Ang-2 and VEGF-A to stabilize blood vessels and reduce vision-threatening conditions
Ref: Roche | Image: Roche
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
